Answers from the Lab

Many laboratorians are not patient-facing. So, while laboratories are critical to patient care, they may lack visibility when it comes to policymaking. 

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, discuss their leadership roles in national advocacy organizations and the importance of laboratorian engagement in the federal regulatory process.

(00:31)
 Would each of you share a little bit about yourselves and your backgrounds?
 

(01:47)
 Could you provide us with an overview of what the WGSDX test is?

(02:26)
 How is that different from other genetic tests, like exome or microarray?

(03:56)
 Tell us more about who benefits from these tests.

(07:17)
 Is this test recommended by expert groups?

(09:10)
 How do providers go about ordering this test, and what sample types are accepted?

(11:12)
 What type of variants are detected by this test?

(13:04)
 How would you say our test matches up to other genome tests available on the market?

(14:04)
 What about medically actionable secondary findings?

(14:55)
 Are there any other unique features?

(16:07)
 Could you summarize the benefits of doing WGSDX at Mayo?

(00:31)
 Could you provide a little bit about yourself and your background?

(02:04)
 Could you provide an overview of the chromosomal microarray assay?

(05:49)
 Why should the chromosomal microarray assay be used over other available assays, such as FISH?

(08:56)
 Does the chromosomal microarray provide good benefits in terms of gain of 7 and loss of 10, and EGFR amplification?

(12:03)
 What's the value of utilizing the test alongside a neuro-specific NGS panel, such as Mayo Clinic Laboratories' NONCP panel?

(17:20)
 How are the results used in patient care?

(19:41)

Is there anything else you feel it's important to highlight?

Norovirus is the No. 1 cause of foodborne illness in the United States. And while most people who contract norovirus recover on their own without the need for testing or treatment, others do not. 

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, discuss what’s behind recent outbreaks of norovirus and how to keep yourself healthy and protected throughout the remainder of this year’s peak norovirus season. 

(00:31):

Before we get started, can you tell us a little bit about yourselves and your backgrounds?

(02:35):
Can you guys give us a brief overview of this assay and what will be changing to characterize marijuana use?

(04:28):
So which patients should have this testing and when would you say it should be performed, Dr. Langman?

(05:58):
Are there other test options available and if, and if so, how do these compare?

(07:03):
This is really the best way to accurately characterize marijuana use. Would you say that's true?

(07:11):
And then could you, Dr. Langman, explain how the results are used in patient care?

(00:32)
 Can you tell our audience a little bit about yourself and your role here at Mayo Clinic?

(01:29)
 Can you tell our listeners a little bit about the disease state when we talk about autoimmune or paraneoplastic movement disorders?

(02:37)
 Are we seeing an increased prevalence of autoimmune movement disorders?

(04:00)
 Can you give our listeners an overview of what's going to be launched here in January?

(06:56)
 What other antibodies are particularly important in this phenotype?

(10:01)
 How does the kelch-like protein 11 phenotype manifest in this disorder?

(10:49)
 Are there any antibodies in the autoimmune neurology space that would not need to be evaluated for in patients that present with some sort of movement disorder? 

(11:18)
 Which patients should have this testing and when should it be performed?

(12:55)
 When should Mayo Clinic Laboratories' stiff person evaluation and standalone glycine receptor tests be used, and in what order?

(14:40)
 Is the movement disorder evaluation the right first choice when the patient presentation is less typical and includes ataxia?

(16:42)
 Can physicians order the glycine receptor standalone test to fully evaluate the spectrum of antibodies?

(18:39)
 How does the evaluation impact patient care?

(20:12)
 Have these new antibodies been shown to be immunotherapy-responsive?

(20:27)
 Is there a key takeaway with the launch of these new antibodies in the movement disorder evaluation?

(00:31)
 Could you provide our listeners with a little bit about yourself and your background?

(01:48)
 Could you give an overview of the new neuro-oncology expanded gene panel by next generation sequencing?

(03:43)

Can you describe a little bit more about some examples of genes that were in the 2021 WHO classification that are now included in the NONCP panel?

(06:50)
 Does this panel have high clinical utility in both in adult and pediatric cases?

(08:05)
 Is picking up on copy numbers useful in both adult and pediatric cases?

(09:12)
 Could you discuss a little bit more about how these results would be used in patient care?

(10:27)
 Do you have anything else you would like to add about the enhanced neuro-oncology NGS panel?